Department of Cancer Biology

We are delighted to announce that our colleague, Dr. Małgorzata Kubiak, Lecturer in the Institute of Biology at Warsaw University of Life Sciences, has been awarded the prestigious PRELUDIUM 22 grant by The National Science Center. Her groundbreaking research project titled “Investigation of the effect of hypoxia on the metabolism of exogenous ferritin and its role in the regulation of free iron in macrophages and cancer cells” secured funding amounting to PLN 70,000.

This commendable achievement marks a significant milestone in Dr. Kubiak’s career, enabling her to delve into crucial research focusing on understanding the intricate mechanisms of hypoxia’s impact on cellular metabolism, particularly in macrophages and cancer cells.

The OPUS 25 and PRELUDIUM 22 competitions, spearheaded by NCN, are instrumental in fostering basic research endeavors within the scientific community. These grants empower researchers at different stages of their careers, facilitating the exploration of diverse scientific realms.

This year, a total of 407 projects were selected for funding under these competitions, amounting to an impressive PLN 338 million. Notably, with a frozen budget, the success rate stood at 8.06% for OPUS and 10.73% for PRELUDIUM, reflecting the exceptional caliber and rigor of the selected projects.

Congratulations to Dr. Małgorzata Kubiak and the six other scientists from the Warsaw University of Life Sciences who have been recognized for their exemplary contributions to fundamental research. Their dedication and expertise exemplify the spirit of scientific inquiry driving innovation and progress in our community.

#ResearchExcellence #ScienceGrants #NCNResearch #FundamentalResearch #InnovationInScience

https://www.sggw.edu.pl/narodowe-centrum-nauki-oglosilo-wynikikonkursow-opus-25-i-preludium-22/

 Prof. Magdalena Król is set to join the EIC Tech to Market (T2M) “Business Idea Validation Bootcamp” starting November 14th! This 4-week program uses the Design Thinking Methodology to help researchers, like Prof. Król, transition from lab research to impactful innovation. With personalized support, feedback from industry experts, and tailored training, she’ll be refining her project’s value proposition and aligning it with market needs. Here’s to a transformative journey from research to real-world impact! 🌐 #EICT2MBootcamp #InnovationJourney #BusinessValidation

Make sure to check this program: https://eic.eismea.eu/community/events/eic-t2m-business-idea-validation

Prof. Magdalena Król, Head of Department, wowed the audience at BIO-Europe in Munich, Germany with her captivating speech on “Breakthrough Macrophage-Based Immunotherapy for Solid Tumors.”

A big shoutout to the organizers for creating a platform for groundbreaking ideas. We’re inspired and eager to see how this innovation will shape the future of cancer treatment! 🌟🙌 #BIOEurope #Immunotherapy

🌟🎓 What a Day to Celebrate! 🎓🌟

We are absolutely thrilled to share some wonderful news from our Cellis family. Today, our colleague Małgorzata Kubiak successfully defended her doctoral thesis! 🎉📚

Małgorzata’s journey has been one of dedication, perseverance, and sheer brilliance. Her unwavering commitment to research, together with the invaluable guidance of her thesis supervisors, prof. dr hab. Magdalena Król and dr Paulina Kucharzewska-Siembieda, have played a pivotal role in her success. 🤩👏🤩

Throughout her time with us at Cellis, Małgorzata has continually inspired us all with her intellect and unyielding passion for her field. Her remarkable thesis is not only a testament to her hard work but also a valuable contribution to the world of science. 🌍🔬

Today, we not only celebrate her academic success but also the embodiment of the Cellis spirit – the pursuit of excellence, teamwork, and the drive to make a positive impact on the world. 🌟

As Małgorzata takes this significant step forward in her career, we are excited to witness her continued growth and the incredible contributions she will undoubtedly make to her field and to our organization. 🌠

Join us in congratulating Małgorzata on this monumental achievement. 🎉👏 We couldn’t be prouder, and we can’t wait to see what the future holds for this brilliant researcher and our incredible Cellis family. 🚀🌻 #CellisSuccess #DoctoralThesisDefended #ProudMoment

Dear Students and Future Innovators,

Exciting opportunities await you at Cellis in our cutting-edge research laboratory. Prof. Magdalena Król, CEO at Cellis and a professor at Warsaw University of Life Sciences (WULS – SGGW), is eager to welcome talented students to collaborate on groundbreaking projects.

Why Choose Us?

🎓 Explore cutting-edge research

🎓 Benefit from world-class mentorship

🎓 Write your thesis on impactful projects

🎓 Network with like-minded professionals

Ready to be a part of our team? Apply via our website: http://www.krol-lab.sggw.pl/index.php/students/ 

Join us in shaping the future of life sciences! 🌱 #ResearchOpportunities #StudentThesis #ScienceMatters

🌟 #ThrowbackThursday to an Inspiring Interview! 🌟

🔗 Read the full article here: https://www.cost.eu/eu_prize_women_innovators/ 

Let’s take a moment to reflect on the remarkable achievements of women innovators shaping our future. Today, we’re throwing it back to an incredible interview with Prof. Magdalena Król, CEO at Cellis.

Magdalena’s groundbreaking work has earned her a spot among the finalists for the prestigious EU Prize for Women Innovators 2020, funded by the EU’s Horizon 2020 program. This award recognizes exceptional female entrepreneurs driving innovation across various industries to tackle global challenges head-on. The groundbreaking research awarded with the Prize has directly influenced the current advancements in therapy, paving the way for transformative breakthroughs in the field.

In the interview, Magdalena shares her captivating journey from becoming a full Professor at Warsaw University of Life Sciences to co-founding Cellis, an innovative company revolutionizing cancer treatment. Their pioneering research harnesses the power of macrophages, leveraging a breakthrough technology called Macrophage-Drug Conjugates (MDCs). By selectively targeting solid tumors, they’re transforming the prognosis for patients with unmet medical needs.

So, join us in celebrating Magdalena’s phenomenal accomplishments and the impact of women innovators worldwide. Let’s fuel our curiosity, embrace diversity, and continue pushing boundaries for a brighter, more innovative future! 🌟💡 #tbt #LinkedIn #WomenInnovation #GameChangers #Inspiration #EUHorizon

Prof. Magdalena Król, Head of the Department, will be participating in the upcoming #ASCO2023 event! As one of the most highly anticipated oncology conferences of the year, American Society of Clinical Oncology (ASCO) provides an invaluable platform for industry leaders, researchers, and healthcare professionals to collaborate, share insights, and advance the fight against cancer.

Event Details:
📅 Date: June 2-6, 2023
📍 Location: Chicago, USA
🔗 Learn more about ASCO2023: https://lnkd.in/eAiKEdE
🔗 Register for partneringONE® meetings: https://lnkd.in/dkhQ2UtD

During ASCO2023, Connecting Cancer is offering you a unique opportunity to connect with Magdalena Król and arrange one-to-one meetings through partneringONE®. Whether you are attending the conference in person or virtually, partneringONE® ensures you can engage directly with key players in the field, fostering meaningful collaborations and driving innovation.

Let’s come together, share knowledge, and drive progress in oncology! See you at ASCO2023!